Swiss Healthtech Startup Oviva Secures $21 Million Series B Investment

15.01.2020 09:24, Gianmaria Sbetta

The Venture Leaders China alumn has announced the closing of the Series B financing round with international investors such as MTIP, Earlybird, and existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures and Partech.

Oviva, a Zurich-based company, is a leading provider of technology-enabled medical nutritional therapy by applying technology to improve patient experience, care efficiency and effectiveness. Specifically, the startup focuses on a digital solution to stop the progression of and reverse Type 2 diabetes and obesity-related conditions. The team has reached so far important milestones, have treated 90,000 patients in the last three years across the U.K., Germany, France, Switzerland and the UAE.

Founder and CEO Kai Eberhardt, a former Venture Leaders China alumn, has announced today the closing of a $21 million Series B fundraising round. The new capital injection will support technology and platform development and growth activities in Europe. To date, Oviva has raised a total of $34 million.

"Venture Leaders China was an excellent program, opening up perspectives on a new market and immediate business opportunities. The organization was excellent, really supporting startups becoming successful and growing in important markets." Kai Eberhardt
 

Follow Kai and apply now to Venture Leaders China!